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Abstract
Background & Aims—The diagnosis of drug-induced liver injury relies upon exclusion of
other causes, including viral hepatitis A, B, and C. Hepatitis E virus (HEV) infection has been
proposed as another cause of suspected drug-induced liver disease. We assessed the frequency of
HEV infection among patients with drug-induced liver injury in the United States.
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Methods—The drug-induced liver injury network (DILIN) is a prospective study of patients with
suspected drug-induced liver injury; clinical information and biological samples are collected to
investigate pathogenesis and disease progression. We analyzed serum samples, collected from
patients enrolled in DILIN, for immunoglobulin (Ig)G and IgM against HEV; selected samples
were tested for HEV RNA.
Results—Among 318 patients with suspected drug-induced liver injury, 50 (16%) tested positive
for anti-HEV IgG and 9 (3%) for anti-HEV IgM. The samples that contained anti-HEV IgM
(collected 2 to 24 weeks after onset of symptoms) included 4 that tested positive for HEV RNA,
genotype 3. Samples from the 6-month follow-up visit were available from 4 patients; they were
negative for anti-HEV IgM, but levels of anti-HEV IgG increased with time. Patients that had anti-
HEV IgM were mostly from older men (89%; mean age, 67 years) and 2 were HIV positive.
Clinical reassessment of the 9 patients with anti-HEV IgM indicated that acute hepatitis E was the
most likely diagnosis for 7 and might be the primary diagnosis for 2.
Conclusion—HEV infection contributes to a small but important proportion of cases of acute
liver injury that are suspected of being drug induced. Serologic testing for HEV infection should
be performed—particularly if clinical features are compatible with acute viral hepatitis.
Keywords
Viral hepatitis; jaundice; isoniazid; liver biopsy; causality assessment; liver disease; drug toxicity;
treatment; cirrhosis
Introduction
Drug-induced liver injury is the leading cause of acute liver failure and the primary reason
for regulatory action leading to failed drug approval, market withdrawal, usage restrictions
and warnings to practicing physicians in the United States.1 The diagnosis of drug-induced
liver injury is often difficult because of the lack of specific biomarkers and the diversity of
its clinical presentation.2 The diagnosis is primarily one of exclusion and is made only after
elimination of common causes of liver disease, such as alcoholic hepatitis, metabolic and
genetic liver diseases, bile duct obstruction, and hepatitis A, B, and C virus infection (HAV,
HBV, and HCV).
Hepatitis E virus (HEV) infection is another cause of acute liver injury but is rarely
considered in the differential diagnosis of drug-induced liver injury, largely because
hepatitis E is thought to be rare in the Western World and unlikely to occur unless there is a
history of recent travel to an endemic area such as Asia, Africa or Central or South
America.3 Several recent findings have served to alter this opinion. First, indigenous cases
of acute hepatitis E have been reported in the United States as well as Europe, Japan, and
New Zealand caused by HEV genotype 3 strains which are endemic to domestic and wild
animals, particularly swine.4-12 In addition, recent population-based surveys in the United
States have shown that at least 20% of adults are reactive for IgG anti-HEV, and thus have
serological evidence of previous HEV infection.13,14 Finally, a publication from the United
Kingdom suggested that up to 12% of cases of acute liver injury initially attributed to
medications were actually due to unsuspected acute HEV infection.15
The aims of the current study were to assess whether acute hepatitis E accounts for some
cases of suspected drug-induced liver injury in the United States and whether testing for
HEV infection is warranted in the routine evaluation of patients with acute liver disease of
unknown cause.
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Patient identification and causality analysis
The Drug Induced Liver Injury Network (DILIN) consists of multiple (previously 5, and
currently 8) U.S. clinical sites and a data coordinating center that have enrolled patients with
suspected drug-induced liver injury into a prospective study since 2004. The rationale,
design and conduct of the DILIN, as well as a summary of the first 300 enrolled cases have
been described.16,17 All enrolled cases were subjected to formal causality assessment
independently by three investigators, and a final causality score was obtained by
consensus.18 At the same time, a Roussel Uclaf Causality Assessment (RUCAM) score19
was determined and cases were graded for severity using a five-point scale developed by the
DILIN.16
Serologic and Virologic Testing
Serum samples were obtained at the time of enrollment, which might be as long as 6 months
after the onset of liver injury, and were stored at -80 degrees Celsius in a central repository.
For the current study, serum samples from the first 318 patients enrolled were tested for IgM
and IgG anti-HEV using enzyme immunoassays of established sensitivity and
specificity.20,21 Samples with IgM anti-HEV and those with strongly positive reactions for
IgG anti-HEV were further tested for HEV RNA using nested reverse transcription
polymerase chain reaction (RT-PCR)22 and the PCR products were separated by
electrophoresis on ethidium bromide-stained agarose gels, extracted from the gel and
directly sequenced to provide the consensus sequence. A BLAST search of GenBank
nucleotide sequences was performed to determine HEV genotype. Details of the ELISA
assays for anti-HEV and the PCR for HEV RNA are provided in Supplementary Material.
Histological Analysis
When available, liver biopsies (n=3) were reviewed by a hepatic pathologist (D.E.K.) who
was unaware of the medications implicated and results of HEV testing. Histological features
of inflammation, fibrosis, steatosis, cholestasis, vascular injury and other findings were
systematically recorded, along with a description of the overall pattern of injury.
Repeat Causality Analysis
Cases positive for HEV IgM were subjected to repeat causality analysis by three
independent reviewers after the results of HEV serological and RT-PCR testing were
available. Cases were again judged for the likelihood that the implicated medication was
responsible for the liver injury as “definite” (>95% likelihood), “highly likely” (75-94%),
“probable” (50-74%), “possible” (25-49%) or “unlikely” (<25%).18 Cases were also judged
using the same scale as to the likelihood that the liver injury was due to acute hepatitis E
based upon the clinical, biochemical and histological findings.
Data analysis
Pairwise comparisons were performed between the cases with no serological evidence of
HEV infection versus patients with evidence of active or recent HEV infection (defined by
presence of HEV IgM) and those with distant and resolved HEV infection (defined by
presence of IgG without IgM anti-HEV). The Wilcoxon test was used for continuous
variables, Fisher’s exact test for binary outcomes, and the Pearson chi-squared test for other
categorical variables.
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All details of the DILIN Prospective study were reviewed and approved by the institutional
review boards of each clinical site and the data coordinating center. Each enrolled subject
signed an informed consent that allowed future testing on archived biosamples. In addition,
the protocol for anti-HEV testing was specifically approved by the institutional review board
of the National Institute of Allergy and Infectious Diseases of the intramural program of the
National Institutes of Health.
Results
Serological Testing
Among 318 patients tested, 50 (16%) were reactive for IgG anti-HEV, 9 of whom (3%) were
also reactive for IgM anti-HEV. The demographical and clinical features of patients with
both IgG and IgM anti-HEV (Group 1, n=9), with IgG anti-HEV alone (Group 2, n=41), and
with no markers of HEV infection (Group 3, n= 268) are shown in Table 1. Comparing the
three groups, patients with anti-HEV reactivity were on average older (67 and 62 versus 47
years: both comparisons p = 0.001) and those with IgM anti-HEV were more often men
(90% versus 44% and 41%: p = 0.003). Initial and peak serum bilirubin, alanine
aminotransferase (ALT) and alkaline phosphatase levels were similar in the three groups of
patients. Furthermore, the three groups did not different in distribution of pattern of serum
enzyme elevations, severity scores or causality scores.
Demographic and Clinical Features of IgM anti-HEV Positive Cases
Selective demographic and clinical features of the nine IgM anti-HEV positive cases are
given in Table 2, and detailed case summaries of each patient are provided as
Supplementary Data. The cases included eight men and one woman; eight were non-
Hispanic whites and one was multiracial. The average age was 67 years (range 42 to 83
years). Initial serum bilirubin levels ranged from 0.4 to 15.1 mg/dL (mean = 7.0 mg/dL) and
peak levels were only slightly higher (mean = 10.8 mg/dL). Initial ALT levels ranged from
196 to 3838 U/L (mean = 1073 U/L) and alkaline phosphatase from 113 to 632 U/L (mean =
225 U/L). Based upon calculation of the R score (ALT divided by alkaline phosphatase both
expressed as multiple of the upper limit of the normal range19), the biochemical pattern of
serum enzyme elevations was hepatocellular (R > 5) in 5, cholestatic in 1 (R < 2) and
“mixed” in 3 (R 2-5). Three patients gave a history of fever and one of rash, but these
symptoms were not prominent and no patient had documented eosinophilia. Antinuclear
antibody was present in low titers in two patients (1:40 and 1:80) and smooth muscle
antibody in seven (titers ranging from 1:8-1:320) but other autoimmune features (arthritis,
rash, hyperglobulinemia) were not common. All patients were symptomatic, eight were
jaundiced, and seven were hospitalized for the liver injury. The clinical course was
considered severe in three patients who manifested signs of hepatic failure such as
elevations in INR > 1.5, ascites or hepatic encephalopathy. Two of these patients had a
clinical syndrome resembling “acute on chronic” hepatitis, both having evidence of pre-
existing liver disease (alcoholic and nonalcoholic fatty liver disease).
Information on exposures to farm animals or raw pork was not specifically sought but none
offered such information or gave a history of travel to an endemic area. One patient became
ill while travelling to Prague, Czech Republic, but symptoms arose upon his arrival, making
infection from exposure in the United States more likely. The patients were geographically
diverse and presented at 4 of the 5 DILIN centers including Indiana (n=5), San Francisco
(n=2), Connecticut (n=1) and North Carolina (n=1) between 2004 and 2006. The initially
implicated medications included nevirapine (as a part of antiretroviral therapy) in two
patients, and isoniazid, allopurinol, telithromycin, pravastatin, ezetimibe, azithromycin and
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an herbal product in one case each. The latency to first documented laboratory abnormalities
ranged from 13 days to 12.7 years, being less than one month in two, 1 to 6 months in four
and greater than 6 months in three cases.
HEV RNA results
Four patients with IgM anti-HEV were also reactive for HEV RNA, and all four harbored
genotype 3. Sequencing analyses showed that the four were not closely related
phylogenetically (data not shown) and therefore were not likely due to a single source or
contamination, presenting in different geographic areas (Indiana, San Francisco and North
Carolina). The four cases with viremia included both patients with HIV infection. Follow-up
serum samples, drawn approximately 6 months after enrollment, were available from four
IgM anti-HEV-positive subjects: all had an increase in IgG anti-HEV titer, but IgM anti-
HEV had diminished in titer or had become negative, consistent with seroconversion after
acute infection. All were also negative for HEV RNA (two were positive on the earlier
specimen) (Table 3).
Causality Analysis/Re-analysis
The initial causality assessment for the nine cases concluded that 4 were highly likely, 3
probably and 2 possibly due to drug-induced liver injury. RUCAM scores of cases ranged
from 5 to 10, values of 3 to 5 (n=1) indicating a “possible”, values of 6 to 8 (n=5) a
‘probable” and those above 8 (n=3) a “highly probable” likelihood.21 Thus, most cases were
considered compatible with drug-induced liver injury on initial assessment in the absence of
anti-HEV results.
On reassessment after the results of anti-HEV testing were available, the causality scores
changed in eight cases (remaining “possible” in one) and no case was considered more than
“probably” due to drug-induced liver injury (Table 2). Even with the information on HEV
serology, two cases (implicated medications being allopurinol and telithromycin) were still
considered probably due to drug-induced liver injury rather than hepatitis E. Both patients
presented late during the course of illness and initial clinical features and laboratory results
were not available. The remaining seven cases were considered more likely to be acute
hepatitis E than drug-induced liver injury, although four were still considered “possibly” due
to the medication. Three cases were considered “definite” acute hepatitis E.
Liver histology of IgM anti-HEV positive cases
Liver biopsy tissue was available from three patients. Case 2 developed serum enzyme
elevations without jaundice during antiretroviral therapy that persisted for 4 months and had
a liver histology (Figure 1) suggestive of chronic hepatitis with focal bridging necrosis and
hepatocyte rosette formation, minimal steatosis, a lymphocytic portal infiltrate with
scattered eosinophils and only rare plasma cells, and bridging fibrosis. The bile ducts
showed mild injury with reactive changes, but without cholestasis. Case 4 developed mild
acute liver injury with jaundice after taking ezetimibe for one year and underwent liver
biopsy during recovery when serum bilirubin (1.4 mg/dL) and ALT levels (60 U/L) were
close to normal. The biopsy (not shown) showed mild steatosis, ballooning and bridging
fibrosis with focal copper accumulation consistent with nonalcoholic steatohepatitis which
he was thought to have before onset of the acute injury (based upon chronic ALT elevations
and obesity). Hepatocyte rosetting was also present which is atypical of nonalcoholic fatty
liver disease and is consistent with regeneration following a more severe injury in the
immediate past. Case 7 developed jaundice and a hepatitis-like syndrome 1.5 years after
starting an antiretroviral regimen including nevirapine and on liver biopsy (Figure 2) had
changes of lobular disarray, spotty hepatocyte necrosis without confluence, marked lobular
but scant portal inflammation, mild intrahepatic cholestasis but no bile duct injury, steatosis
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or fibrosis. These changes were compatible with either viral hepatitis or acute hepatocellular
drug injury.
Discussion
The accurate diagnosis of drug-induced liver injury is critically important not only for
patient care, but also for drug development, as even a single episode of severe liver damage
associated with a drug during pre-marketing clinical testing may undermine its subsequent
approval and marketing.25 For the patient, the occurrence of liver injury may preclude the
use of a medication that is critically needed such as a first-line anticonvulsant, anti-retroviral
or anti-tuberculosis medication. Nevertheless, the accurate diagnosis of drug-induced liver
disease is challenging, not only because of the lack of specific markers, but also because the
clinical features are non-specific and often similar to those that occur in acute viral hepatitis
or other causes of liver injury. In essence, the diagnosis requires exclusion of a wide array of
other causes of liver injury, including viral and autoimmune hepatitis, bile duct obstruction,
sepsis, hepatic ischemia, and metabolic disorders.2
While viral serology for hepatitis A, B and C are part of the standard evaluation of suspected
drug-induced liver disease, testing for evidence of HEV infection is rarely done, largely
because this form of acute viral hepatitis is considered rare in developed countries.3,26
Indeed, until recently almost all reported cases of hepatitis E in the United States were
described in travelers returning from endemic areas of infection, such as Asia, Northeast
Africa, the Middle East, and Mexico. However, there have been increasing numbers of cases
of indigenous or “autochthonous” HEV infection described in patients in developed
countries who deny travel to endemic areas.4-12,15,27-30 These non-travel associated cases
are typically caused by genotype 3 HEV which is commonly found in swine even in
developed countries.4,10,11,21,24 Indeed, careful medical history of non-travel related cases
has often identified exposure to domesticated and wild animals or recent consumption of
undercooked pork or wild game.6,10-12 Finally, recent reports have demonstrated that
chronically immunosuppressed patients, such as organ transplant recipients or HIV infected
individuals, can develop chronic HEV infection with high levels of virus and may represent
a reservoir for human infection in western countries.31,32 Importantly, chronic HEV
infection can lead to progressive hepatic fibrosis, cirrhosis and end-stage liver disease, and
recent pilot studies have suggested that chronic HEV infection can be eradicated by a
relatively short course of peginterferon or ribavirin.33,34
In this study, evidence of HEV infection was sought in an unselected group of cases of drug-
induced liver injury that had been accrued at five medical centers in the United States
between the years 2004 and 2009. Nine of 318 cases (3%) had serological evidence of
ongoing or recent acute hepatitis E. Interestingly, all except one patient was male and the
average age was almost 2 decades older than the cohort of patients without anti-HEV
reactivity. These findings are similar to reports on indigenous cases of hepatitis E from the
United Kingdom, in which 78% of cases were in men and the average age was 65 years.30
The reasons for these associations are not known. One explanation is that genotype 3 HEV
infection may be largely subclinical in young, healthy individuals and more likely to be
symptomatic and icteric in older men or patients with significant co-morbidities. Indeed,
among the nine patients described here, eight had major co-morbidities including HIV
infection, chronic obstructive pulmonary disease, asthma, alcoholism, obesity, tuberculosis,
diabetes, atherosclerotic cardio- or cerebro-vascular disease, and lymphoma. In the absence
of specific testing, it is not surprising that hepatitis E and drug-induced injury might be
confused clinically; the clinical features of hepatitis E like those of other forms of acute
hepatitis can resemble hepatitis caused by medications.15,26,29,35
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A careful reanalysis of the nine cases of suspected drug-induced liver injury that were
positive for IgM anti-HEV, however, demonstrated that some cases were still considered to
be more likely due to drug hepatotoxicity than acute hepatitis E. These findings suggest that
the recent acute HEV infection detected by IgM anti-HEV testing did not account for the
acute liver injury in all cases and that co-incidental, subclinical hepatitis E may have
preceded the acute liver injury caused by the implicated medication.
An important finding of this study was that four cases had HEV RNA detectable in serum,
all of which were genotype 3. These results indicate that the acute hepatitis E is due to local
sources, possibly related to exposure to farm animals or eating pork. Two cases occurred in
patients with HIV infection who were on chronic antiretroviral therapy, the liver injury
initially being attributed to nevirapine. Indeed, one of the patients had chronic hepatitis on
liver biopsy and was still HEV RNA positive almost 24 weeks after initial presentation with
serum enzyme elevations. Such findings suggest that immunosuppressed individuals should
avoid eating undercooked pork or game, and that such individuals with chronic unexplained
liver disease should be tested for HEV infection.
In the remaining five patients the absence of viremia may have been due to the delay
between the onset of symptoms and blood sampling for the study, as patients were typically
referred by local physicians to the DILIN investigators days or even weeks after initial
presentation. Thus, the nine blood samples were obtained an average of 37 days after onset
of illness. In previous studies of acute hepatitis E, IgM anti-HEV was generally present in
serum when symptoms arose and persisted for 4 to 6 months after resolution, whereas HEV
RNA was detectable during the incubation period of the disease and early during the clinical
illness; and in some cases was not longer detectable by the time of onset of jaundice or
clinical symptoms.3,34,35 In studies of acute hepatitis in which patients were tested at or near
the onset of illness, serum HEV-RNA was detected in only 50-66% of anti-HEV IgM
positive cases.30,36 HEV RNA is also detectable in stool during the acute phase of infection,
although the reliability of testing stool versus serum has not been adequately evaluated.
While acute hepatitis E due to genotype 1 tends to be symptomatic and icteric, the clinical
spectrum of genotype 3 HEV infection has not been fully defined. The patients described
here often had severe liver injury. Eight patients were jaundiced, the single anicteric case
appearing to have chronic hepatitis E (in the setting of HIV infection). Three patients
developed features of hepatic failure including two with an “acute-on-chronic” syndrome
developing hepatic encephalopathy and/or ascites concurrent with onset of jaundice.
Nevertheless, the high rate of anti-HEV positivity in the U.S. population14 suggests that
many cases of acute HEV infection are subclinical. Indeed, among the 9 patients described
here, 2 were considered still to have drug-induced liver injury and a recent subclinical HEV
infection.
Another explanation for the current results is false positivity in the serological assays. This
explanation, however, is unlikely because highly validated assays for IgM and IgG anti-
HEV were used, four cases were reactive for HEV RNA in serum, and follow up testing in
four subjects demonstrated a decline in IgM and rise in IgG anti-HEV titers. At present,
there are no FDA approved assays for anti-HEV with proven specificity and sensitivity.
Research testing results can be obtained from the Centers for Disease Control and
Prevention (http://www.cdc.gov/hepatitis/) or by special arrangements with research
laboratories. The results of the current study demonstrate the critical need for commercially
available, sensitive and reliable assays for IgM anti-HEV and HEV RNA.
In summary, a small proportion of cases of suspected drug-induced liver injury in the United
States may be related to concurrent and unsuspected acute hepatitis E. Testing for HEV
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infection should be considered when the pattern of injury resembles acute viral hepatitis and
when features of the clinical presentation and latency (time to onset) are unusual. Such
testing is particularly apropos when the medications are critically important (e.g.,
antiretrovirals, anti-tuberculosis agents). Testing for IgG anti-HEV alone is not helpful
because 20% or more of otherwise healthy adults in Western countries are likely to test
positive.13,14 Tests for IgM anti-HEV are most appropriate for screening for acute infection,
with positive results confirmed by HEV RNA testing or follow up serology (disappearance
of IgM anti-HEV and appearance or rise in titer of IgG anti-HEV). The presence of
serological evidence of acute hepatitis E should also prompt a search for possible sources of
infection, such as foreign travel, exposure to farm animals, consumption of undercooked
pork or wild game, and close personal contact with chronically immunosuppressed persons.
Finally, these findings underscore the need for sensitive and reliable, commercially available
assays for HEV infection in the United States and reexamination of the possible benefit of
an HEV vaccine.37,38
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Liver injury initially attributed to nevirapine (Case #2) and later considered probably
due to chronic HEV infection
a. The portal area is expanded by a chronic inflammatory infiltrate with interface hepatitis
indicative of chronic hepatitis. Several eosinophils are present (H&E, 400x). b. There is
portal fibrotic expansion with early bridging fibrosis. Ductular reaction is present at the
edges of the portal areas (Masson trichrome, 200x).
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Figure 2. Acute liver injury attributed to nevirapine (Case #7) and later considered due to
hepatitis E
a. The biopsy shows an acute hepatitis pattern with mild canalicular cholestasis. There portal
inflammation with many plasma cells and a few eosinophils and moderate interface
hepatitis. The parenchyma shows and numerous foci of lobular inflammation with acidophil
bodies (H&E, 200x). b. There is early periportal fibrosis and mild ductular reaction (Masson
trichrome, 200x).
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